TY - JOUR
T1 - Co-infection with HPV types from the same species provides natural cross-protection from progression to cervical cancer
AU - Sobota, Rafal S.
AU - Ramogola-Masire, Doreen
AU - Williams, Scott M.
AU - Zetola, Nicola M.
N1 - Funding Information:
RSS was supported by Public Health Service award T32 GM07347 from the National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program. SMW and RSS were partially supported by NIH grant P20 GM103534. NMZ was supported in part by NIH grants R01AI097045 and P30AI45008 (Penn Center for AIDS Research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2014 Sobota et al.; licensee BioMed Central Ltd.
PY - 2014/8/12
Y1 - 2014/8/12
N2 - Background: The worldwide administration of bivalent and quadrivalent HPV vaccines has resulted in cross-protection against non-vaccine HPV types. Infection with multiple HPV types may offer similar cross-protection in the natural setting. We hypothesized that infections with two or more HPV types from the same species, and independently, infections with two or more HPV types from different species, associate with protection from high-grade lesions. Findings. We recruited a cohort of 94 HIV, HPV-positive women from Botswana, with Grade 2 or higher cervical intraepithelial neoplasia. Infections with 2 or more HPV types from a single species associated with reduced lesion severity in univariate analysis (OR = 0.41, 95% CI 0.18-0.97, p = 0.042), when adjusted for the presence of HPV 16 or 18 types (OR = 0.41, 95% CI 0.17-1.00, p = 0.049), or all high-risk HPV type infections (OR = 0.38, 95% CI 0.16-0.90, p = 0.028). Infections with 2 or more HPV types from different species did not associate (OR = 0.68, 95% CI 0.25-1.81, p = 0.435). Conclusions: Our findings show that co-infections with genetically similar HPV types reduce the likelihood of progression to high-grade lesions in HIV positive women, an effect not observed in co-infections with taxonomically different HPV types. This observation is possibly caused by an immune cross-protection through a similar mechanism to that observed after HPV vaccination.
AB - Background: The worldwide administration of bivalent and quadrivalent HPV vaccines has resulted in cross-protection against non-vaccine HPV types. Infection with multiple HPV types may offer similar cross-protection in the natural setting. We hypothesized that infections with two or more HPV types from the same species, and independently, infections with two or more HPV types from different species, associate with protection from high-grade lesions. Findings. We recruited a cohort of 94 HIV, HPV-positive women from Botswana, with Grade 2 or higher cervical intraepithelial neoplasia. Infections with 2 or more HPV types from a single species associated with reduced lesion severity in univariate analysis (OR = 0.41, 95% CI 0.18-0.97, p = 0.042), when adjusted for the presence of HPV 16 or 18 types (OR = 0.41, 95% CI 0.17-1.00, p = 0.049), or all high-risk HPV type infections (OR = 0.38, 95% CI 0.16-0.90, p = 0.028). Infections with 2 or more HPV types from different species did not associate (OR = 0.68, 95% CI 0.25-1.81, p = 0.435). Conclusions: Our findings show that co-infections with genetically similar HPV types reduce the likelihood of progression to high-grade lesions in HIV positive women, an effect not observed in co-infections with taxonomically different HPV types. This observation is possibly caused by an immune cross-protection through a similar mechanism to that observed after HPV vaccination.
KW - Cervical cancer
KW - Coinfection
KW - HPV
KW - Immune cross-protection
KW - Taxonomy
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84906924246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906924246&partnerID=8YFLogxK
U2 - 10.1186/1750-9378-9-26
DO - 10.1186/1750-9378-9-26
M3 - Article
AN - SCOPUS:84906924246
SN - 1750-9378
VL - 9
JO - Infectious Agents and Cancer
JF - Infectious Agents and Cancer
IS - 1
M1 - 26
ER -